Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications.

BACKGROUND Major depressive disorder (MDD) is associated with increased risk for premature coronary heart disease and bone loss. Single time measurements of plasma IL-6, a good predictor of future risk for both cardiovascular disease and osteoporosis, revealed significant elevations in depressed patients. The objective of this study was to rigorously compare plasma IL-6 levels, measured over 24 h, in MDD patients and healthy controls. Given the activating role of IL-6 on the hypothalamic-pituitary-adrenal (HPA) axis, and the relevance of its dysregulation in MDD, we also analyzed the relations between IL-6 and cortisol levels. METHODS We studied nine patients and nine controls, individually matched by gender, age (+/-5 yr), body mass index (+/-2 kg/m2), and menstrual cycle phase. Diagnosis of MDD was confirmed by structured clinical interview based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Axis I diagnostic criteria. Self-reported mood ratings were assessed by multiple visual analog scales. The rhythmicity and complexity of IL-6 and cortisol secretion were tested by cosinor analyses, approximate entropy (ApEn) and cross-ApEn algorithms. RESULTS MDD patients had significant mean IL-6 elevations from 1000-1200 h and at 1500 h (P ranging from <0.05 to <0.01) vs. controls. In addition, in MDD, the circadian rhythm of IL-6 was shifted by 12 h, and its physiological complexity was reduced, with no difference in the cross-ApEn of IL-6 and cortisol between the two groups, and significant time-lagged correlations only in the controls. IL-6 levels correlated significantly with mood ratings. CONCLUSIONS We report profound morning elevations of plasma IL-6 and a reversal of its circadian rhythm in MDD patients, in the absence of hypercortisolism. These findings may be relevant to the increased risk for coronary heart disease and bone loss in MDD.

[1]  J. Weatherbee,et al.  Circadian characteristics of circulating interleukin-6 in men. , 1995, The Journal of allergy and clinical immunology.

[2]  J. Born,et al.  Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. , 1998, The Journal of clinical endocrinology and metabolism.

[3]  B. Giusti,et al.  Interleukin-6 and acute-phase proteins in head and neck cancer , 2004, European Archives of Oto-Rhino-Laryngology.

[4]  R. Jilka,et al.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.

[5]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[6]  I. Heuser,et al.  Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. , 2000, The American journal of psychiatry.

[7]  G. Chrousos.  Stress, chronic inflammation, and emotional and physical well-being: concurrent effects and chronic sequelae. , 2000, The Journal of allergy and clinical immunology.

[8]  Steven M. Pincus,et al.  Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome. , 2001, The Journal of clinical endocrinology and metabolism.

[9]  M. Seibel,et al.  Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. , 2001, The Journal of clinical endocrinology and metabolism.

[10]  G. Chrousos,et al.  Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. , 1997, The Journal of clinical endocrinology and metabolism.

[11]  D. Papanicolaou,et al.  Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. , 1997, Neuroendocrinology.

[12]  G. Chrousos,et al.  Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. , 1993, The Journal of clinical endocrinology and metabolism.

[13]  E P Ahearn,et al.  The use of visual analog scales in mood disorders: a critical review. , 1997, Journal of psychiatric research.

[14]  M. Straume,et al.  Innovative Quantitative Neuroendocrine Techniques , 1999 .

[15]  F. Chiappelli,et al.  Interactions between Glucocorticoids and Cytokines in the Bone Microenvironment , 2002, Annals of the New York Academy of Sciences.

[16]  D. Stirling,et al.  Interleukin 6 and Haemostasis , 2001, British journal of haematology.

[17]  B. Rabin,et al.  Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. , 1993, Endocrinology.

[18]  C. Hack,et al.  Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. , 1991, Surgery.

[19]  C. Nemeroff,et al.  Epidemiology of comorbid coronary artery disease and depression , 2003, Biological Psychiatry.

[20]  E. Bixler,et al.  Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  D. Papanicolaou,et al.  Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. , 2002, Metabolism: clinical and experimental.

[22]  N. Lowe,et al.  A critical review of visual analogue scales in the measurement of clinical phenomena. , 1990, Research in nursing & health.

[23]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[24]  Steven M. Pincus.  Assessing Serial Irregularity and Its Implications for Health , 2001, Annals of the New York Academy of Sciences.

[25]  Kristopher J Preacher,et al.  Chronic stress and age-related increases in the proinflammatory cytokine IL-6 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Brambilla,et al.  Blood levels of cytokines in elderly patients with major depressive disorder , 1998, Acta psychiatrica Scandinavica.

[27]  J. Veldhuis,et al.  Sex-Steroid Interactions with Growth Hormone , 2012, Proceedings in the Serono Symposia USA Series.

[28]  G. Chrousos,et al.  Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. , 1994, The Journal of clinical endocrinology and metabolism.

[29]  G. Chrousos,et al.  Bone mineral density in women with depression. , 1996, The New England journal of medicine.

[30]  B. Barton.  IL-6: insights into novel biological activities. , 1997, Clinical immunology and immunopathology.

[31]  D. Papanicolaou,et al.  The Pathophysiologic Roles of Interleukin-6 in Human Disease , 1998, Annals of Internal Medicine.

[32]  F. Goodwin,et al.  Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2) , 1988, The New England journal of medicine.

[33]  R. Klopp,et al.  Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. , 1993, Lymphokine and cytokine research.

[34]  R. Dantzer,et al.  Cytokine-induced sickness behavior , 2003, Brain, Behavior, and Immunity.

[35]  Steven M. Pincus,et al.  Effects of age on the irregularity of LH and FSH serum concentrations in women and men. , 1997, The American journal of physiology.

[36]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[37]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[38]  D. Healy,et al.  Rhythm and blues. Neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders , 2004, Psychopharmacology.

[39]  E. Bosmans,et al.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.

[40]  F. Anton,et al.  Psychoneuroimmunological correlates of persisting sciatic pain in patients who underwent discectomy , 1997, Neuroscience Letters.

[41]  D. Papanicolaou,et al.  Circadian interleukin-6 secretion and quantity and depth of sleep. , 1999, The Journal of clinical endocrinology and metabolism.

[42]  D. Ford,et al.  Depression is a risk factor for coronary artery disease in men: the precursors study. , 1998, Archives of internal medicine.

[43]  C. Gundberg,et al.  Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. , 2002, The Journal of clinical endocrinology and metabolism.

[44]  Steven M. Pincus,et al.  Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia. , 2001, The Journal of clinical endocrinology and metabolism.

[45]  F. Goodwin,et al.  Evidence that the pathophysiology of depression and the mechanism of action of antidepressant drugs both involve alterations in circadian rhythms. , 1982, Advances in biochemical psychopharmacology.

[46]  Klaus P. Ebmeier,et al.  Diurnal variation of mood and neuropsychological function in major depression with melancholia. , 1994, Journal of affective disorders.

[47]  G. Chrousos,et al.  Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states , 2002, Molecular Psychiatry.

[48]  R. Hermida,et al.  Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. , 1998, Chronobiology international.

[49]  H. Meltzer,et al.  Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. , 1995, Journal of affective disorders.

[50]  R C Hermida,et al.  Chronolab: an interactive software package for chronobiologic time series analysis written for the Macintosh computer. , 1992, Chronobiology international.

[51]  George P Chrousos,et al.  Depression: a major, unrecognized risk factor for osteoporosis? , 2001, Trends in Endocrinology & Metabolism.

[52]  Y. Pollak,et al.  Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. , 2002, The international journal of neuropsychopharmacology.

[53]  D. Papanicolaou,et al.  Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. , 1996, The American journal of physiology.

[54]  C. Tangen,et al.  Depressive Symptoms and Risks of Coronary Heart Disease and Mortality in Elderly Americans , 2000 .